Methods for reducing cd36 expression
AssigneeCornell Research Foundation, Inc.
InventorsHazel H. Szeto, Shaoyi Liu, Sunghee Cho
Life of this patent
Estimating the term…
Abstract
The invention provides a method for reducing CD36 expression in a cell. The method comprises contacting the cell with an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3 pm is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1.
Claims13
A method for reducing CD36 expression in a mammal in need thereof, the method comprising administering to the mammal an effective amount of an aromatic-cationic peptide having:
- (a) at least one net positive charge;
- (b) a minimum of four amino acids;
- (c) a maximum of about twenty amino acids;
- (d) a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3 pm is the largest number that is less than or equal to r+1;
- and
- (e) a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1.
A method for treating a disease or condition characterized by increased CD36 expression in a mammal in need thereof, the method comprising administering to the mammal an effective amount of an aromatic-cationic peptide having:
- (a) at least one net positive charge;
- (b) a minimum of four amino acids;
- (c) a maximum of about twenty amino acids;
- (d) a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3pm is the largest number that is less than or equal to r+1;
- and
- (e) a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1.
A method for treating diabetic nephropathy in a mammal in need thereof, the method comprising administering to the mammal an effective amount of an aromatic-cationic peptide having:
- (a) at least one net positive charge;
- (b) a minimum of four amino acids;
- (c) a maximum of about twenty amino acids;
- (d) a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3 pm is the largest number that is less than or equal to r+1;
- and
- (e) a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1.
Dependencies are inferred from the claim text.